Literature DB >> 18285592

Does this patient with diabetes have osteomyelitis of the lower extremity?

Sonia Butalia1, Valerie A Palda, Robert J Sargeant, Allan S Detsky, Ophyr Mourad.   

Abstract

CONTEXT: Osteomyelitis of the lower extremity is a commonly encountered problem in patients with diabetes and is an important cause of amputation and admission to the hospital. The diagnosis of lower limb osteomyelitis in patients with diabetes remains a challenge.
OBJECTIVE: To determine the accuracy of historical features, physical examination, and laboratory and basic radiographic testing. We searched for systematic reviews of magnetic resonance imaging (MRI) in the diagnosis of lower extremity osteomyelitis in patients with diabetes to compare its performance with the reference standard. DATA SOURCES: MEDLINE search of English-language articles published between 1966 and March 2007 related to osteomyelitis in patients with diabetes. Additional articles were identified through a hand search of references from retrieved articles, previous reviews, and polling experts. STUDY SELECTION: Original studies were selected if they (1) described historical features, physical examination, laboratory investigations, or plain radiograph in the diagnosis of lower extremity osteomyelitis in patients with diabetes mellitus, (2) data could be extracted to construct 2 x 2 tables or had reported operating characteristics of the diagnostic measure, and (3) the diagnostic test was compared with a reference standard. Of 279 articles retrieved, 21 form the basis of this review. Data from a single high-quality meta-analysis were used to summarize the diagnostic characteristics of MRI in osteomyelitis. DATA EXTRACTION: Two authors independently assigned each study a quality grade using previously published criteria and abstracted operating characteristic data using a standardized instrument. DATA SYNTHESIS: The gold standard for diagnosis is bone biopsy. No studies were identified that addressed the utility of the history in the diagnosis of osteomyelitis. An ulcer area larger than 2 cm2 (positive likelihood ratio [LR], 7.2; 95% confidence interval [CI], 1.1-49; negative LR, 0.48; 95% CI, 0.31-0.76) and a positive "probe-to-bone" test result (summary positive LR, 6.4; 95% CI, 3.6-11; negative LR, 0.39; 95% CI, 0.20-0.76) were the best clinical findings. A erythrocyte sedimentation rate of more than 70 mm/h increases the probability of a diagnosis of osteomyelitis (summary LR, 11; 95% CI, 1.6-79). An abnormal plain radiograph doubles the odds of osteomyelitis (summary LR, 2.3; 95% CI, 1.6-3.3). A positive MRI result increases the likelihood of osteomyelitis (summary LR, 3.8; 95% CI, 2.5-5.8). However, a normal MRI result makes osteomyelitis much less likely (summary LR, 0.14; 95% CI, 0.08-0.26). The overall accuracy (ie, the weighted average of the sensitivity and specificity) of the MRI is 89% (95% CI, 83.0%-94.5%).
CONCLUSIONS: An ulcer area larger than 2 cm2, a positive probe-to-bone test result, an erythrocyte sedimentation rate of more than 70 mm/h, and an abnormal plain radiograph result are helpful in diagnosing the presence of lower extremity osteomyelitis in patients with diabetes. A negative MRI result makes the diagnosis much less likely when all of these findings are absent. No single historical feature or physical examination reliably excludes osteomyelitis. The diagnostic utility of a combination of findings is unknown.

Entities:  

Mesh:

Year:  2008        PMID: 18285592     DOI: 10.1001/jama.299.7.806

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  26 in total

1.  Is there a role for imaging in the management of patients with diabetic foot?

Authors:  Vartan M Vartanians; Adolf W Karchmer; John M Giurini; Daniel I Rosenthal
Journal:  Skeletal Radiol       Date:  2009-07       Impact factor: 2.199

Review 2.  Diagnostics and treatment of the diabetic foot.

Authors:  Jan Apelqvist
Journal:  Endocrine       Date:  2012-02-25       Impact factor: 3.633

3.  A purulent foot ulcer in a man with diabetes mellitus.

Authors:  Jeffrey Craig; Yasbanoo Moayedi; Paul E Bunce
Journal:  CMAJ       Date:  2013-03-18       Impact factor: 8.262

4.  Outcomes in diabetic foot ulcer patients with isolated T2 marrow signal abnormality in the underlying bone: should the diagnosis of "osteitis" be changed to "early osteomyelitis"?

Authors:  Dennis Duryea; Stephanie Bernard; Donald Flemming; Eric Walker; Cristy French
Journal:  Skeletal Radiol       Date:  2017-05-11       Impact factor: 2.199

Review 5.  Diabetic Foot Infections: an Update in Diagnosis and Management.

Authors:  Pinelopi Grigoropoulou; Ioanna Eleftheriadou; Edward B Jude; Nikolaos Tentolouris
Journal:  Curr Diab Rep       Date:  2017-01       Impact factor: 4.810

6.  Outcomes of Osteomyelitis in Patients Hospitalized With Diabetic Foot Infections.

Authors:  Dane K Wukich; Kimberlee B Hobizal; Tresa L Sambenedetto; Kristin Kirby; Bedda L Rosario
Journal:  Foot Ankle Int       Date:  2016-08-22       Impact factor: 2.827

7.  Management of diabetic foot infections in an era of increasing microbial resistance.

Authors:  Sandra Bliss Nelson
Journal:  Curr Infect Dis Rep       Date:  2009-09       Impact factor: 3.725

Review 8.  Neuropathic osteoarthropathy with and without superimposed osteomyelitis in patients with a diabetic foot.

Authors:  Antonio Leone; Victor N Cassar-Pullicino; Alessia Semprini; Laura Tonetti; Nicola Magarelli; Cesare Colosimo
Journal:  Skeletal Radiol       Date:  2016-02-17       Impact factor: 2.199

9.  Diagnosing osteomyelitis in the diabetic foot: a pilot study to examine the sensitivity and specificity of Tc(99m) white blood cell-labelled single photon emission computed tomography/computed tomography.

Authors:  Mallory M Przybylski; Samantha Holloway; Steven D Vyce; Antonio Obando
Journal:  Int Wound J       Date:  2014-06-26       Impact factor: 3.315

Review 10.  Musculoskeletal Infections in the Emergency Department.

Authors:  Daniel C Kolinsky; Stephen Y Liang
Journal:  Emerg Med Clin North Am       Date:  2018-09-06       Impact factor: 2.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.